The Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
The Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Mol Oncol. 2022 Sep;16(18):3352-3379. doi: 10.1002/1878-0261.13285. Epub 2022 Jul 28.
Increasing evidence demonstrates that DNA damage and genome instability play a crucial role in ageing. Mammalian cells have developed a wide range of complex and well-orchestrated DNA repair pathways to respond to and resolve many different types of DNA lesions that occur from exogenous and endogenous sources. Defects in these repair pathways lead to accelerated or premature ageing syndromes and increase the likelihood of cancer development. Understanding the fundamental mechanisms of DNA repair will help develop novel strategies to treat ageing-related diseases. Here, we revisit the processes involved in DNA damage repair and how these can contribute to diseases, including ageing and cancer. We also review recent mechanistic insights into DNA repair and discuss how these insights are being used to develop novel therapeutic strategies for treating human disease. We discuss the use of PARP inhibitors in the clinic for the treatment of breast and ovarian cancer and the challenges associated with acquired drug resistance. Finally, we discuss how DNA repair pathway-targeted therapeutics are moving beyond PARP inhibition in the search for ever more innovative and efficacious cancer therapies.
越来越多的证据表明,DNA 损伤和基因组不稳定性在衰老过程中起着关键作用。哺乳动物细胞已经开发出广泛的复杂和协调良好的 DNA 修复途径,以应对和解决来自外源性和内源性来源的许多不同类型的 DNA 损伤。这些修复途径的缺陷会导致加速或过早衰老综合征,并增加癌症发展的可能性。了解 DNA 修复的基本机制将有助于开发治疗与衰老相关疾病的新策略。在这里,我们回顾了 DNA 损伤修复所涉及的过程,以及这些过程如何导致疾病,包括衰老和癌症。我们还回顾了 DNA 修复的最新机制见解,并讨论了如何利用这些见解开发治疗人类疾病的新的治疗策略。我们讨论了 PARP 抑制剂在临床上用于治疗乳腺癌和卵巢癌,以及与获得性药物耐药性相关的挑战。最后,我们讨论了 DNA 修复途径靶向治疗药物如何在寻求更具创新性和疗效的癌症治疗方法方面超越 PARP 抑制。